News
Sanofi takes a hit as hotly tipped breast cancer drug fails ...
Shares in Sanofi were on the slide this morning after the drugmaker revealed that one of its top pipeline prospects – selective oestrogen receptor degrader (SERD) amcenestrant – stumbled in
